Business
JCR Pharmaceuticals to Present at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025
HYOGO, Japan, August 28, 2025--JCR Pharmaceuticals announced that it will present data at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025 next week.
About this update from Jcr Pharmaceuticals Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/0a3da17cc28d8e932e285bb69aac5502"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V6Sas_s1EC5qY5.ylEHKuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0a3da17cc28d8e932e285bb69aac5502","width":480,"height":251}},"lazy":false},{"type":"text","content":"- Data to be showcased in one oral presentation and four poster presentations -","length":79,"tagName":"p","attribs":{}},{"type":"text","content":"HYOGO, Japan, August 28, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced today that it will present data at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025, held September 2-6, 2025, in Kyoto, Japan. The presentations will demonstrate the potential benefits of the investigational therapies in JCR’s development pipeline and of J-Brain Cargo®, JCR’s proprietary technology that delivers medicine across the blood-brain barrier (BBB) for the treatment of lysosomal storage disorders and neurodegenerative disorders.","length":696,"tagName":"p"},{"type":"text","content":"Details of the presentations are as follows:","length":44,"tagName":"p"},{"type":"text","content":"Poster Presentation Title: Therapeutic effect of JR-141 (pabinafusp alfa) on cardiovascular system in a mouse model of mucopolysaccharidosis type IIDate/Time: Wednesday, September 3, 2025, 18:00-19:00 JSTPresenter: Kenta Arisumi (JCR Pharmaceuticals)Poster Number: P-311Abstract Number: 11189","length":296,"tagName":"p"},{"type":"text","content":"Poster Presentation Title: Nonclinical pharmacology of JR-446, a novel blood-brain barrier penetrant α-N-acetylglucosaminidaseDate/Time: Wednesday, September 3, 2025, 18:00-19:00 JSTPresenter: Jun Ito (JCR Pharmaceuticals)Poster Number: BP-15Abstract Number: 11217","length":268,"tagName":"p"},{"type":"text","content":"Poster Presentation Title: Long-term safety of pabinafusp alfa in patients with mucopolysaccharidosis type II: interim 5-year data from a clinical trial in JapanDate/Time: Thursday, September 4, 202...